Back to News
Market Impact: 0.35
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Source: businesswire.com
Healthcare & BiotechCompany Fundamentals
Organon reported positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through six years of use, with no new safety signals. The brief report provides no efficacy figures or additional trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
OGN0.75
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated